Citations

Clear

3942 citation(s) found for "To, Van".

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database
Jin, Zhaohui , Dixon, Jesse G. , Fiskum, Jack, Yothers, Greg , Allegra, Carmen J. , Haller, Daniel G. , Gramont, Aimery de , Taı̈eb, Julien , Tweleves, Christopher, Sadahiro, Sotaro , Blanke, Charles D. , Tomita, Naohiro , Seitz, Jean‐François, Erlichman, Charles , Yamanaka, Takeharu , Goldberg, Richard M. , George, Thomas J. , Fiskum, Jack M, Yothers, Greg , Haller, Daniel , Kerr, Rachel , Taieb, Julien , Twelves, Christopher , O'Connell, Michael, Saltz, Leonard , Marsoni, Silvia , André, Thierry , Mahipal, Amit , Goldberg, Richard M , George, Thomas J , Shi, Qian , Jin, Zhaohui , Dixon, Jesse G , Parekh, Hiral D. , Sinicrope, Frank A. , Wolmark, Norman , Schmoll, Hans‐Joachim , Kerr, Rachel , Cutsem, Eric Van , Twelves, Chris , O’Connell, Michael J. , Saltz, Leonard B. , Yoshino, Takayuki , Marsoni, Silvia , André, Thierry , Mahipal, Amit , Shi, Qian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 21, 2021 | Volume: 113 | Issue: 12 | Pages: 1693-1704

10.1093/jnci/djab123 | PMID 34405233 Get It

Abstract Background Colon cancer (CC) incidence in young adults (age 20-49 years), termed early-onset CC (EO-CC), is increasing. Methods Individual patient data on 35 713 subjects with stage III colon cancer from 25 randomized studies in the Adjuvant Colon Cancer ENdpoint database were pooled. The distributions of demographics, clinicopathological features, biomarker status, and outcome data were summarized by age group. Overall survival, disease-free survival, time to recurrence, and survival after recurrence were assessed by Kaplan-Meier curves and Cox models stratified by treatment arms within studies, adjusting for sex, race, body mass index, performance status, disease stage, grade, risk group, number of lymph nodes examined, disease sidedness, and molecular markers. All statistical tests were 2-sided. Results Using a 5% difference between age groups as the clinically meaningful cutoff, patients with stage III EO-CC had similar sex, race, performance status, risk group, tumor sidedness, and T stage compared with patients with late-onset CC (age 50 years and older). EO-CC patients were less likely to be overweight (30.2% vs 36.2%) and more commonly had 12 or more lymph nodes resected (69.5% vs 58.7%). EO-CC tumors were more frequently mismatch repair deficient (16.4% vs 11.5%) and less likely to have BRAFV600E (5.6% vs 14.0%), suggesting a higher rate of Lynch syndrome in EO-CC. Patients with EO-CC had statistically significantly better overall survival (hazard ratio [HR] = 0.81, 95% confidence interval [CI] = 0.74 to 0.89; P < .001), disease-free survival (HR = 0.91, 95% CI = 0.84 to 0.98; P = .01), and survival after recurrence (HR = 0.88, 95% CI = 0.80 to 0.97; P = .008) in the analysis without molecular markers; however, age at onset of CC lost its prognostic value when outcome was adjusted for molecular markers. Conclusion Tumor biology was found to be a more important prognostic factor than age of onset among stage III colon cancer patients in the Adjuvant Colon Cancer ENdpoint database.
Abstract 424: Transintestinal Cholesterol Excretion Can Drive Massive Cholesterol Elimination in Mice
Boer, Jan Freark de , Schonewille, Marleen, Boesjes, Marije, Wolters, Henk, Bos, Trijnie , Dijk, Theo H. van , Jurdzinski, Angelika, Boverhof, Renze, Deursen, Jan M. van , Kremoser, Claus, Groen, Albert K., Bloks, Vincent W. , Elferink, Ronald P.J. Oude , Moschetta, Antonio , Verkade, Henkjan J. , Kuipers, Folkert

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 21, 2021 | Volume: 36 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.36.suppl_1.424 Get It

High plasma cholesterol levels increase the risk of cardiovascular disease (CVD). Transintestinal Cholesterol Excretion (TICE) is a recently emerged pathway of cholesterol removal and has the potential to lower plasma cholesterol levels and confer protection against CVD. Under control conditions, TICE accounts for about 30% of fecal cholesterol loss in mice. Using a panel of knock-out and transgenic mice as well as pharmacological manipulations we show that in mice TICE is regulated by intestinal activation of the Farnesoid X Receptor (FXR), via its target Fibroblast Growth Factor 15/19 (FGF15/19). Activation of FXR by the agonist PX20606 (PX) resulted in a >10-fold increased fecal cholesterol excretion as well as TICE and 40% reduced plasma cholesterol levels. The induction of fecal cholesterol excretion and TICE was absent in PX-treated intestine-specific FXR-null mice but was regained when those mice were co-treated with FGF19. Moreover, FGF19 treatment alone was sufficient to induce fecal cholesterol loss to a similar extend as was observed in PX-treated wild-type mice. PX treatment resulted in an increased muricholate/cholate-ratio and thereby induced a more hydrophilic bile salt pool. Not surprisingly, cholesterol absorption was reduced in PX-treated mice. However, experiments in which mice were co-treated with PX and the cholesterol absorption inhibitor ezetimibe revealed that the stimulating effect of PX on fecal neutral sterol excretion and TICE were completely independent of differences in cholesterol absorption. Of note, treatment of mice with a combination of PX and ezetimibe stimulated fecal cholesterol loss and TICE so strongly that those mice lost about 60% of their entire estimated body cholesterol content each day. The stimulation of fecal cholesterol loss and TICE by PX and PX/ezetimibe treatment was severely blunted in Abcg8-KO mice and this could not be restored by hepatic reintroduction of Abcg8, indicating a decisive role for intestinal ABCG5/G8 in PX-induced fecal cholesterol loss and TICE. Our data strongly suggest that hydrophilic bile acids stimulate ABCG5/G8 activity in the intestine, leading to an increased flux of cholesterol from the body into the intestinal lumen that is subsequently excreted with the feces.
Abstract 470: Computational Identification of NKX2-5 Binding Sites and Downstream Gene Targets Using Transcription Factor Motif and Human Heart-specific Experimental Data
Tan, Nicholas Y. , Chung, Mina K. , Smith, Jonathan D. , Wagoner, David R. Van , Barnard, John

Mayo Clinic

Circulation Research | June 21, 2021 | Volume: 119 | Issue: suppl_1 | Pages: No page available

10.1161/res.119.suppl_1.470 Get It

Background: While NKX2-5 plays pivotal roles in human cardiac development and disease, no ChIP-Seq studies of NKX2-5 in human cardiac tissues currently exist, resulting in an incomplete understanding of its direct gene targets. Modern computational methods which identify binding sites using transcription factor motif and tissue-specific experimental data can help to fill this knowledge gap. Objective: To use computational methods to identify likely NKX2-5 binding sites and downstream gene targets using human heart-specific experimental data. Methods: Human cardiomyocyte DNAse hypersensitivity data (2 replicates) were downloaded from the Encyclopedia of DNA Elements (ENCODE) database. The position weight matrix (PWM) representing the transcription factor motif of NKX2-5 was obtained from JASPAR. We applied the Protein Interaction Quantification (PIQ) algorithm to detect NKX2-5 binding sites using the PWM and DNAse hypersensitivity data as inputs. RNA-Seq data from 108 human heart-specific samples (atrial appendages and left ventricles) were downloaded from the Genotype-Tissue Expression (GTEx) database. Protein-coding genes significantly expressed in the heart (RPKM <= 1 based on the GTEx RNA-Seq data) that were within 100kb of the predicted binding sites were then identified. Pathway analysis of these genes was performed using Ingenuity Pathway Analysis (IPA). Results: 1283 binding sites for NKX2-5 were discovered by PIQ. Of 12698 protein-coding, heart-expressed genes, 625 were within 100kb of these binding sites. The identified genes were highly enriched in physiologic categories like “Vasculogenesis” and “Development of Cardiovascular Tissue” (p = 2.36x10-9 and 2.31x10-8 respectively). Notable genes included: cardiac transcription factors (MEF2A, TBX20); growth factors (TGFB2, BMP2); muscle and ion channel function (ACTA2, BIN1), and; calcium signaling (CALM2, CAMK2D). Conclusion: By using computational analyses of transcription factor motif and human heart-specific experimental data, we have identified candidate downstream targets of NKX2-5. Future work will include validation studies in an external cohort and analysis of associations between these candidate genes and cardiac disease.
Abstract 019: Real-World Use of Sacubitril/ Valsartan in Heart Failure in the First Year Following FDA Approval
Sangaralingham, Lindsey R. , Sangaralingham, S. Jeson , Houten, Holly K. Van , Shah, Nilay D. , Adigun, Rosalyn , Sangaralingham, S. Jeson , Dunlay, Shannon M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.019 Get It

Background: In July 2015, the FDA approved the use of sacubitril/ valsartan in patients with heart failure (HF) and reduced ejection fraction. It was shown in a large clinical trial to reduce the risk of both hospitalization and death compared with enalapril, and has since received a class I recommendation for use in the 2016 ACC/ AHA HF guidelines. However, the use of sacubitril/ valsartan in a clinical practice has not been described. We aimed to assess the uptake and cost of sacubitril/ valsartan in its first year following FDA approval. Methods: Using a large U.S. insurance database, we identified privately insured and Medicare Advantage (MA) patients who filled a first prescription for sacubitril/ valsartan between July 1, 2015 and July 31, 2016. We restricted to persons with medical and pharmacy enrollment for 6 months prior to first fill. For reference, we identified all individuals with a diagnosis of HF on a billing claim (ICD9 428.X or ICD-10 I50.X) in the same time period. Results: There were 314,410 individuals with a diagnosis of HF in the study period. In total, 972 filled a new prescription for sacubitril/ valsartan, and the number of new users steadily increased over time (Figure). The mean age of sacubitril/ valsartan users was 68.1±12.3 years, 32.5% were women, 61.1% were white, and 77% were enrolled in MA plans. Most prescribing clinicians were cardiologists (82.5%). A majority of prescription costs were covered by the health plan (mean $324.05, median $335.38, interquartile range [IQR] $266.56-$370.10). Out-of-pocket (OOP) costs per 30-day prescription filled were variable (mean $101.53, median $45.00, IQR $7.40-$97.49), and were similar in beneficiaries enrolled in MA and commercial plans. By comparison, median OOP costs were $2-4 for lisinopril, losartan, carvedilol, and spironolactone per 30-day prescription. Discussion: These finding suggest that the uptake of sacubitril/ valsartan has been slow in the first year after FDA approval. While the majority of prescription costs are covered by the health plan, OOP costs are still much higher than other guideline-recommended HF medications. Further studies are needed to determine if uptake of sacubril/ valsartan continues to rise and if the higher prescription cost is associated with lower downstream costs of hospitalization and mortality benefit.
Relationship of VO 2 with Cardiac Hemodynamics Improves During Exercise in Cystic Fibrosis Patients
Wheatley, Courtney M. , Baker, Sarah , Snyder, Eric M., Iterson, Erik H. Van

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 29 | Issue: S1 | Pages: No page available

10.1096/fasebj.29.1_supplement.675.9 Get It

Background Although lower vs. healthy individuals, diffusion capacity of lungs for carbon monoxide (DL CO ) and nitric oxide (DL NO ) (may influence oxygen uptake, VO 2 ) are higher during exercise vs. rest in cystic fibrosis patients (CF). Thus, because the Fick equation suggests cardiac output (Q) increases linearly with VO 2 , we sought to study relationships between VO 2 with cardiac function from rest to peak exercise as increases in Q, DL CO and DL NO occur during exercise in CF. Methods 50 individuals participated (ages 22 ± 2 vs. 27 ± 2, BSA = 1.7 ± 0.1 vs. 1.8 ± 0.0 m 2 , VO 2peak = 24 ± 2 vs. 35 ± 2 ml/kg/min, CF (n = 19) vs. controls (CTL, n = 31), mean ± SEM, p<0.05 for all). Acetylene rebreathe was used to assess Q and calculate stroke volume (SV), and standard gas‐exchange was used to assess VO 2 (mL/kg/min). Cardiac power (CP, Q i × MAP) and stroke work (SW, SV i × MAP) were calculated. Q and SV were indexed to BSA (Q i and SV i ). Results Linear regression (R 2 ) between VO 2 with SV i , Q i , CP, and SW at rest were similarly negligible for CF vs. CTL (p=ns). At 50 % VO 2peak , R 2 between VO 2 with SV i (0.25 and 0.43, p<0.05), Q i (0.37 and 0.41, p<0.05), CP (0.18, p=ns and 0.25, p<0.05), and SW (0.12 and 0.30, p=ns) improved for CF and CTL, respectively. At VO 2peak , stronger R 2 between VO 2 with SV i (0.41, p<0.05), Q i (0.47, p<0.05), CP (0.24, p<0.05), and SW (0.19, p=ns) occurred in CF; but, R 2 weakened in CTL (0.28, p<0.05; 0.33, p<0.05; 0.07, p=ns; 0.02, p=ns, respectively). Conclusions From rest to VO 2peak the relationship between VO 2 with cardiac function improves in CF patients. Participation in exercise may benefit relationships between gas‐transfer with cardiac hemodynamics in CF patients.
Sympathetic Neuro‐Hemodynamic Transduction at Rest in Subjects with Low and High Tolerance to Simulated Blood Loss
Bukartyk, Jan , Miller, Andrew D. , Helmond, Noud van , Baker, Sarah E. , Miller, Andrew D, Convertino, Víctor A. , Joyner, Michael J.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.lb266 Get It

Background Central hypovolemia elicited by hemorrhage triggers sympathetically‐mediated baroreflex responses to maintain organ perfusion through peripheral vasoconstriction; humans with low tolerance (LT) to central hypovolemia have a diminished vasoconstrictor response during progressive reductions in central volume. Using the lower body negative pressure (LBNP) hemorrhage model, we tested the hypothesis that humans with LT to central hypovolemia would display attenuated resting beat‐to‐beat neuro‐hemodynamic transduction of muscle sympathetic nerve activity (MSNA) compared to those with high tolerance (HT). Methods MSNA (microneurography, peroneal nerve) and diastolic arterial pressure (DAP; finger photoplethysmography) were recorded in 33 human subjects (23 men, 10 women, age: 31 ± 9 years, BMI: 26 ± 4 kg/m 2 ) who subsequently underwent LBNP to tolerance (onset of pre‐syncopal symptoms) – Figure 1. Consistent with previous studies, subjects were classified as LT if they experienced pre‐syncopal symptoms prior to completing LBNP of −60 mm Hg, or as HT if they experienced pre‐syncopal symptoms after completing LBNP of −60 mm Hg. We performed linear regression analysis on data of binned MSNA burst areas against DAP; the slope of this regression represents transduction. Results Of the 33 subjects, 8 exhibited LT (time to pre‐syncope for LT: 17 ± 2 min and HT: 27 ± 5 min) Contrary to our hypothesis, resting beat‐to‐beat neuro‐hemodynamic transduction was not different between LT and HT subjects (median 0.09 IQR 0.03 – 0.16 mmHg (%s) − 1 vs. median 0.12 IQR 0.06 – 0.16 mmHg (%s) − 1 , respectively, p = 0.44) and was not related to time to pre‐syncope ( p = 0.70). Conclusion Tolerance to simulated blood loss is not related to resting sympathetic neuro‐hemodynamic transduction. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Deoxyhemoglobin Kinetics During Low Intensity Exercise Step‐transitions in Aging Men and Women
Barstow, Thomas J. , Bruhn, Eric J., Simmons, Benjamin, Olson, Thomas P. , Iterson, Erik H. Van , Smith, Joshua R.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.853.21 Get It

Introduction Age related declines in oxidative metabolic capacity have been attributed to slowing of O 2 delivery and utilization. While these declines are pronounced in postmenopausal women, it is unclear how these changes compare with age‐matched men. This study aimed to phenotype adjustments of muscle oxy‐ and‐ deoxygenation during transitions of low intensity fixed‐load exercise in postmenopausal women and age‐matched men. Methods Healthy postmenopausal women (PW) and men (M) (N = 7 and 6; age 57 ± 7 and 61 ± 10 years; BMI 26 ± 2 and 27 ± 4 kg/m 2 , respectively, all P >0.05) completed 3 identical 8 min transients of fixed pedal rate (=35) and load (=20W) ergometry wearing bilateral thigh cuffs. After 5 min of rest, exercise began with 3 min without thigh cuff inflation followed by 5 min of exercise+cuff inflation at 90 mm Hg (to provoke locomotor congestion). Deoxy (HHb)‐ and total (Hb tot )‐ hemoglobin were measured by near‐infrared spectroscopy (NIRS) at the right calf. Data were sampled at 1 s intervals and ensemble averaged across 3 transients and binned to 10 s epochs for each participant prior to mono‐exponential modeling: Y B + A [1 − e −(t‐TD)/τ ]; where Y B = baseline value of Y for the 30 s prior to the step transition; τ = time constant; A = asymptote; TD = time delay. Mean response time (MRT) = TD + τ. Kinetics were modelled for the transition from exercise without to exercise+cuff inflation. Results Following the exercise on‐transient, TD was 9±4 vs. 7±3 s (P=0.35) and 8±4 vs. 6±3 s (P=0.28) for PW vs. M prior to the rise in ΔHHb or ΔHb tot , respectively. For PW vs. M, the A representing the rise in ΔHHb was 8±7 vs. 15±7 μM (P=0.04) and for ΔHb tot it was 13±8 vs. 18±8 μM (P=0.17), respectively. The kinetics of HHb following the exercise+cuff onset were similar for PW and M (τ=53±38 vs. 34±9 s, respectively, P=0.36) as well as for Hb tot (τ=43±29 vs. 29±16 s, respectively, P=0.43). The overall time course for the change in HHb (MRT=62±35 vs. 41±8 s, P=0.27) or Hb tot (MRT=51±27 vs. 35±14 s, P=0.31) did not differ for PW and M, respectively. Conclusions Despite age‐matched men demonstrating greater ΔHHb compared with PW, these data do not support the hypothesis that following exercise onset, the rate of locomotor hemodynamic adjustment and O 2 extraction for a given metabolic demand differ between these groups. Thus, as opposed to gross factors of blood flow and O 2 delivery, effects such as slowing of the rate of activation and/or processes regulating oxidative phosphorylation and mitochondrial respiration may play a stronger role in explaining differences in oxidative metabolic capacity between PW and M. Support or Funding Information Funding for this work was supported by National Institutes of Health [RO1‐HL126638 to TPO]; and American Heart Association [16POST30260021 to EHV] and National Institutes of Health [HL138814 to EHV]. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Mechanisms of Exercise Intolerance in Heart Failure with Reduced Ejection Fraction: Influence of COPD
Olson, Thomas P. , Smith, Joshua R. , Iterson, Erik H. Van

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.853.11 Get It

Introduction Exercise intolerance is a hallmark of heart failure with reduced ejection fraction (HFrEF) resulting from a variety of factors including comprised oxygen delivery. A common comorbidity of HFrEF is chronic obstructive pulmonary disease (COPD), which is independently associated with reduced exercise tolerance and cardiac output (Q) as well as peripheral dysfunction similar to HFrEF. It is currently unknown if HFrEF and coexisting COPD (HFrEF+COPD) exhibit worsened exercise tolerance and whether the mechanisms thereof are similar to HFrEF alone. We hypothesized that patients with HFrEF+COPD demonstrate further reductions in peak VO 2 and workload subsequent to a lower peak Q and arterio‐mixed venous O 2 content difference (C(a‐v)O 2 ) compared to HFrEF alone. Methods HFrEF+COPD (n=16) and HFrEF (n=17) (age: 57±7 vs 54±6 yrs; EF%: 20±5 vs 21±5; height: 173±7 vs 174±7 cm; weight: 88±14 vs 86±17 kg; all p>0.18) underwent peak exercise testing during right heart catheterization. At rest and peak exercise, invasive hemodynamic, cardiac pressures, and arterial pressures were performed. Heart rate and oxygen uptake (VO 2 ) were measured at rest and peak exercise via 12‐lead ECG and metabolic measurement system, respectively. Convective oxygen delivery was calculated as Q multiplied by CaO 2 . Results Peak exercise VO 2 and workload were lower in HFrEF+COPD compared to HFrEF (7.0±1.9 vs. 9.9±2.7 mL/min/kg; 34±7 vs. 45±12 watts; both p<0.01). At peak exercise, Q and stroke volume were lower in HFrEF+COPD than HFrEF (4.8±1.3 vs. 7.0±3.0 L/min; 52±16 vs. 75±28 mL; both p<0.01). Significant relationships existed between delta VO 2 and Q (peak exercise minus resting) in HFrEF+COPD and HFrEF (r=0.84 and r=0.89; both p<0.01); however, HFrEF+COPD had a significantly lower slope (p=0.02). Peak exercise C(a‐v)O 2 was not different between HFrEF+COPD and HFrEF (12.9±2.3 vs. 12.8±2.6 mL/dL; p=0.89). No differences were present in heart rate or hemoglobin at peak exercise (p>0.73). Delta VO 2 and C(a‐v)O 2 was significantly related for HFrEF+COPD (r=0.68; p<0.01), but not HFrEF (r=0.14, p=0.57). At peak exercise, HFrEF+COPD had lower convective oxygen delivery (845±239 vs. 1230±517 mL/min; p<0.01). Conclusions Patients with HFrEF and concurrent COPD demonstrate worsened exercise tolerance compared to HFrEF resulting from reduced oxygen delivery. These data suggest HFrEF with COPD exhibit more severe central and peripheral abnormalities than HFrEF alone. Support or Funding Information NHLBI RO1 HL126638 This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Mitotic Inheritance of mRNAs encoding Transcription factors in Osteoblastic Cells.
Khani, Farzaneh , Takai, Hideki , Galindo, Mario , Stein, Gary S. , Wijnen, André J. van

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.788.12 Get It

Both genomic and non‐genomic mechanisms control the acquisition of specialized cellular phenotypes during development. When differentiated cells enter and exit mitosis, chromosomal condensation prevents gene expression. Post‐mitotic re‐activation of transcription is controlled in part by epigenetic marks on DNA and histones that control chromatin accessibility. However, mRNA molecules also appear to be transferred to progeny cells by either symmetrical or asymmetrical transmission. We have shown that the mRNA for the bone‐related transcription factor Runx2 mRNAs is elevated in the G2 phase of the cell cycle, but not translated in osteoblasts. This observation suggests that Runx2 protein is translationally rather than transcriptionally controlled after mitosis to maintain the phenotypic identity of osteoblasts. We used RNA‐seq expression profiling to assess whether there are other gene regulatory factors that are transmitted through mitosis. Our main results show that mRNAs for transcription factors are typically depleted during mitosis. For example, while Runx2 mRNA is retained in mitotic cells, expression of the closely related genes Runx1 and Runx3 is reduced. Strikingly, expression of Osterix/Sp7 and MEF2C, two transcription factors known to cooperate biologically with Runx2 in promoting the osteoblastic state, is selectively retained in mitotic cells. Our data suggest that selective somatic transmission of mRNAs for transcription factors in osteoblasts may be a general mechanism by which cells maintain their identity during cell division in skeletal development. Support or Funding Information NIH R01 AR049069 This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Seven‐In‐Absentia (SINA) Family E3 Ligases in Development and Growth
Cao, Yajun , Sciver, Robert E. Van , Ahmed, Atique U. , Tang, Amy

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.533.52 Get It

The RAS signal transduction cascade is a pivotal signaling pathway that controls numerous fundamental cellular processes, such as cell proliferation, differentiation, motility, and apoptosis. Oncogenic K‐RAS pathway activation is detected in approximately 30% of all human cancers. Seven‐IN‐Absentia (SINA) is an evolutionarily conserved E3 ubiquitin ligase that is the most downstream signaling module identified in the RAS signaling pathway. Underscoring the importance of SINA is its high evolutionary conservation with over 83% amino acid identity shared between Drosophila SINA and its human SINA homologs (SIAHs). As a major signaling hub and the downstream signaling “gatekeeper” in the RAS pathway, SIAHs are uniquely positioned to inhibit “undruggable” oncogenic K‐RAS activation that is prevalent in high‐grade metastatic cancer. Thus, it is important to delineate the enzymatic activity, molecular regulation, and substrate targeting mechanism(s) of this highly conserved family of SINA/SIAH E3 ligases. By deploying the elegant and powerful Drosophila photoreceptor cell development system, we conducted a genetic modifier screen and identified 28 new sina mutant alleles that exhibit a range of mutant phenotypes. For example, sina complete loss of function (null alleles) is cell lethal, suggesting that SINA is an essential gene in development. All other sina mutant alleles exhibit stronger phenotypes than the previously published sina 2 and sina 3 alleles, providing us with an opportunity to study sina loss‐of‐function mutant phenotypes. Sequencing analysis of these newly identified mutant alleles reveals the critical roles of several immutatable amino acid residues essential for SINA function. To demonstrate the functional conservation of SINA/SIAH proteins, we have generated a collection of transgenic fly lines that carry either wild‐type (WT) or dominant negative (DN) Dm SINA and human SIAH. The altered Dm SINA/hSIAH expression under the control of sev ‐, GMR ‐, and dpp ‐ and salivary gland ‐GAL4 drivers revealed the biological consequences of gain of function and/or loss of function of Dm SINA/hSIAH1/2 in transmitting RAS signaling in central nervous system (CNS) and peripheral nervous system (PNS) development. Immunofluorescent staining of developing imaginal discs and electron micrographs of adult tissues show that ectopic expression of SINA WT/DN /SIAH WT/DN in neurons resulted in dramatic changes in neuronal cell fate in the developing eye and notum. Furthermore, immunofluorescent staining of larval salivary glands revealed a critical role for SINA family E3 ligases in regulation of cell shape, focal adhesions, and cellular junctions. The results from these transgenic animals suggested that Drosophila SINA and human SIAH1/SIAH2 are evolutionarily conserved and functionally interchangeable. Through this developmental neurobiology and cellular biology‐based study, we aim to dissect the molecular action of SINA/SIAH1/2 in RAS signaling. Furthermore, we hope to translate these findings to demonstrate the anticancer efficacy of the next‐generation anti‐SIAH‐based anti‐K‐RAS strategy against high‐grade metastatic human cancer in the future. Support or Funding Information Extramural funding support provided by NIH NIGMS R01 GM069922Z‐05S1 and NCI R01 CA140550. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .